Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
BackgroundAlthough the number of studies on sorafenib for hepatocellular carcinoma (HCC) is increasing during the past two decades, no detailed scientometric examination of its knowledge framework has been undertaken. Therefore, we performed a bibliometric analysis on this topic.MethodsVOSviewer and...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1507608/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132108908953600 |
|---|---|
| author | Wenjun Meng Yihang Luo Lu Zhao Yaoyu Zhang Jiyan Liu Shadan Li Yang Du Hongshuai Li |
| author_facet | Wenjun Meng Yihang Luo Lu Zhao Yaoyu Zhang Jiyan Liu Shadan Li Yang Du Hongshuai Li |
| author_sort | Wenjun Meng |
| collection | DOAJ |
| description | BackgroundAlthough the number of studies on sorafenib for hepatocellular carcinoma (HCC) is increasing during the past two decades, no detailed scientometric examination of its knowledge framework has been undertaken. Therefore, we performed a bibliometric analysis on this topic.MethodsVOSviewer and CiteSpace were utilized to analyze the articles regarding sorafenib for HCC from 2005 to 2024, which were retrieved from the Web of Science Core Collection (WoSCC) database.ResultsThere were 7,667 articles related to sorafenib in HCC were retrieved from the WoSCC database, and they covered 99 countries/regions, 5,640 institutions, and 30,450 authors. The most published literature of countries and institutions were China and Sun Yat-sen University, respectively. Cancers is the journal with the most papers published in this field, and the journal with the most co-citations is N Engl J Med. Among authors, Masatoshi Kudo has published the most research papers, and the most co-citations go to JM Llovet. The keywords “survival”, “apoptosis”, “efficacy”, “transarterial chemoembolization”, “lenvatinib”, etc. represent the current hotspots in this field.ConclusionsWe identified current hotspots and trends by bibliometric analysis in sorafenib-HCC field, which might provide valuable guidance for future researches. Further explorations are supposed to conduct the continued study of HCC apoptosis, large-scaled clinical trials with international cooperations, and comprehensive treatments including multiple systemic or locoregional approaches in patients with HCC. |
| format | Article |
| id | doaj-art-a0370940384d4faa83889fcbef50fd0d |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-a0370940384d4faa83889fcbef50fd0d2025-08-20T02:32:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.15076081507608Bibliometric study on the utilization of sorafenib in hepatocellular carcinomaWenjun Meng0Yihang Luo1Lu Zhao2Yaoyu Zhang3Jiyan Liu4Shadan Li5Yang Du6Hongshuai Li7Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Urology, The General Hospital of Western Theater Command, Chengdu, ChinaDepartment of Urology, The General Hospital of Western Theater Command, Chengdu, ChinaDepartment of Urology, The General Hospital of Western Theater Command, Chengdu, ChinaDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Urology, The General Hospital of Western Theater Command, Chengdu, ChinaDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaBackgroundAlthough the number of studies on sorafenib for hepatocellular carcinoma (HCC) is increasing during the past two decades, no detailed scientometric examination of its knowledge framework has been undertaken. Therefore, we performed a bibliometric analysis on this topic.MethodsVOSviewer and CiteSpace were utilized to analyze the articles regarding sorafenib for HCC from 2005 to 2024, which were retrieved from the Web of Science Core Collection (WoSCC) database.ResultsThere were 7,667 articles related to sorafenib in HCC were retrieved from the WoSCC database, and they covered 99 countries/regions, 5,640 institutions, and 30,450 authors. The most published literature of countries and institutions were China and Sun Yat-sen University, respectively. Cancers is the journal with the most papers published in this field, and the journal with the most co-citations is N Engl J Med. Among authors, Masatoshi Kudo has published the most research papers, and the most co-citations go to JM Llovet. The keywords “survival”, “apoptosis”, “efficacy”, “transarterial chemoembolization”, “lenvatinib”, etc. represent the current hotspots in this field.ConclusionsWe identified current hotspots and trends by bibliometric analysis in sorafenib-HCC field, which might provide valuable guidance for future researches. Further explorations are supposed to conduct the continued study of HCC apoptosis, large-scaled clinical trials with international cooperations, and comprehensive treatments including multiple systemic or locoregional approaches in patients with HCC.https://www.frontiersin.org/articles/10.3389/fonc.2024.1507608/fullsorafenibhepatocellular carcinomaliver cancerapoptosisbibliometric analysis |
| spellingShingle | Wenjun Meng Yihang Luo Lu Zhao Yaoyu Zhang Jiyan Liu Shadan Li Yang Du Hongshuai Li Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma Frontiers in Oncology sorafenib hepatocellular carcinoma liver cancer apoptosis bibliometric analysis |
| title | Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma |
| title_full | Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma |
| title_fullStr | Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma |
| title_full_unstemmed | Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma |
| title_short | Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma |
| title_sort | bibliometric study on the utilization of sorafenib in hepatocellular carcinoma |
| topic | sorafenib hepatocellular carcinoma liver cancer apoptosis bibliometric analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1507608/full |
| work_keys_str_mv | AT wenjunmeng bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT yihangluo bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT luzhao bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT yaoyuzhang bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT jiyanliu bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT shadanli bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT yangdu bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma AT hongshuaili bibliometricstudyontheutilizationofsorafenibinhepatocellularcarcinoma |